Compare Stocks: ITRM, PULM, GELS, and SNOA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GELS Gelteq	$0.55 -0.7%	$0.62	$0.39 ▼ $2.01	$5.89M	-0.41	8.99 million shs	79,280 shs
ITRM Iterum Therapeutics	$0.03	$0.03	$0.03 ▼ $1.42	$1.60M	2.96	4.85 million shs	N/A
PULM Pulmatrix	$1.61 -3.6%	$1.57	$1.16 ▼ $5.50	$6.10M	1.9	45,781 shs	11,937 shs
SNOA Sonoma Pharmaceuticals	$1.27 +2.0%	$1.27	$0.85 ▼ $4.60	$5.96M	1.31	53,692 shs	24,295 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GELS Gelteq	-8.47%	-5.12%	-3.00%	-13.11%	-62.07%
ITRM Iterum Therapeutics	0.00%	0.00%	0.00%	0.00%	-96.15%
PULM Pulmatrix	-0.89%	+17.19%	+4.37%	+1.83%	-63.30%
SNOA Sonoma Pharmaceuticals	-0.40%	-1.19%	-7.78%	+11.16%	-69.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GELS Gelteq	$0.55 -0.7%	$0.62	$0.39 ▼ $2.01	$5.89M	-0.41	8.99 million shs	79,280 shs
ITRM Iterum Therapeutics	$0.03	$0.03	$0.03 ▼ $1.42	$1.60M	2.96	4.85 million shs	N/A
PULM Pulmatrix	$1.61 -3.6%	$1.57	$1.16 ▼ $5.50	$6.10M	1.9	45,781 shs	11,937 shs
SNOA Sonoma Pharmaceuticals	$1.27 +2.0%	$1.27	$0.85 ▼ $4.60	$5.96M	1.31	53,692 shs	24,295 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GELS Gelteq	-8.47%	-5.12%	-3.00%	-13.11%	-62.07%
ITRM Iterum Therapeutics	0.00%	0.00%	0.00%	0.00%	-96.15%
PULM Pulmatrix	-0.89%	+17.19%	+4.37%	+1.83%	-63.30%
SNOA Sonoma Pharmaceuticals	-0.40%	-1.19%	-7.78%	+11.16%	-69.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GELS Gelteq	1.00	Sell	N/A	N/A
ITRM Iterum Therapeutics	1.67	Reduce	N/A	N/A
PULM Pulmatrix	1.00	Sell	N/A	N/A
SNOA Sonoma Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ITRM, PULM, GELS, and SNOA Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/22/2026	GELS Gelteq	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/21/2026	SNOA Sonoma Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	PULM Pulmatrix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	SNOA Sonoma Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	PULM Pulmatrix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	SNOA Sonoma Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	PULM Pulmatrix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/26/2026	GELS Gelteq	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GELS Gelteq	$110K	53.16	N/A	N/A	$1.08 per share	0.51
ITRM Iterum Therapeutics	$390K	4.10	N/A	N/A	($0.15) per share	-0.20
PULM Pulmatrix	$7.81M	0.75	N/A	N/A	$2.45 per share	0.66
SNOA Sonoma Pharmaceuticals	$19.53M	0.31	N/A	N/A	$0.65 per share	1.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GELS Gelteq	-$4.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	-$24.77M	-$0.75	N/A	N/A	N/A	N/A	N/A	-65.54%	N/A
PULM Pulmatrix	-$5.16M	-$1.10	N/A	N/A	N/A	N/A	-125.65%	-95.19%	11/5/2026 (Estimated)
SNOA Sonoma Pharmaceuticals	-$3.17M	-$1.22	N/A	N/A	N/A	-10.33%	-21.41%	-6.08%	11/16/2026 (Estimated)

Latest ITRM, PULM, GELS, and SNOA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	PULM Pulmatrix	-$2.00	-$0.29	+$1.71	-$0.29	N/A	N/A
8/6/2026	Q1 2027	SNOA Sonoma Pharmaceuticals	-$0.30	$0.02	+$0.32	-$0.09	$4.99 million	$6.41 million
6/30/2026	Q2 2026	GELS Gelteq	N/A	-$0.12	N/A	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GELS Gelteq	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	N/A
SNOA Sonoma Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GELS Gelteq	N/A	0.09	N/A
ITRM Iterum Therapeutics	N/A	2.13	1.96
PULM Pulmatrix	N/A	4.70	4.70
SNOA Sonoma Pharmaceuticals	N/A	2.99	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GELS Gelteq	N/A
ITRM Iterum Therapeutics	9.21%
PULM Pulmatrix	11.84%
SNOA Sonoma Pharmaceuticals	1.95%

Insider Ownership

Company	Insider Ownership
GELS Gelteq	N/A
ITRM Iterum Therapeutics	2.00%
PULM Pulmatrix	0.62%
SNOA Sonoma Pharmaceuticals	1.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GELS Gelteq	8	10.71 million	N/A	N/A
ITRM Iterum Therapeutics	10	53.29 million	52.23 million	Not Optionable
PULM Pulmatrix	2	3.65 million	3.63 million	Not Optionable
SNOA Sonoma Pharmaceuticals	260	4.79 million	4.74 million	Not Optionable

ITRM, PULM, GELS, and SNOA Headlines

Recent News About These Companies

Reviewing Sonoma Pharmaceuticals (NASDAQ:SNOA) and Indivior (NASDAQ:INDV)

September 25 at 4:15 AM | americanbankingnews.com

SCYNEXIS (NASDAQ:SCYX) vs. Sonoma Pharmaceuticals (NASDAQ:SNOA) Critical Survey

September 23 at 4:59 AM | americanbankingnews.com

Head-To-Head Comparison: Lexaria Bioscience (NASDAQ:LEXX) and Sonoma Pharmaceuticals (NASDAQ:SNOA)

September 22 at 6:30 AM | americanbankingnews.com

Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting

August 19, 2026 | tipranks.com

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

August 6, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

August 6, 2026 | benzinga.com

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution

June 30, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity

June 18, 2026 | tipranks.com

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

June 16, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

June 16, 2026 | accessnewswire.comA

What's going on with Sonoma Pharma stock Monday?

April 27, 2026 | msn.com

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

April 25, 2026 | finance.yahoo.com

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

March 24, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

March 24, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey’s Aquanil Brand for Sensitive Skin

March 18, 2026 | freep.comF

Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin

March 18, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

February 10, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

February 10, 2026 | accessnewswire.comA

Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

January 29, 2026 | finanznachrichten.de

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

January 28, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ITRM, PULM, GELS, and SNOA Company Descriptions

Gelteq NASDAQ:GELS

$0.55 0.00 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$0.54 0.00 (-0.55%)

As of 07:57 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Iterum Therapeutics NASDAQ:ITRM

$0.03 0.00 (0.00%)

As of 09/24/2026

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Pulmatrix NASDAQ:PULM

$1.61 -0.06 (-3.59%)

Closing price 03:59 PM Eastern

Extended Trading

$1.62 +0.01 (+0.62%)

As of 07:59 PM Eastern

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.27 +0.03 (+2.01%)

Closing price 03:59 PM Eastern

Extended Trading

$1.28 +0.01 (+1.10%)

As of 07:55 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ITRM, PULM, GELS, and SNOA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ITRM, PULM, GELS, and SNOA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ITRM, PULM, GELS, and SNOA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ITRM, PULM, GELS, and SNOA Company Descriptions

Gelteq NASDAQ:GELS

Iterum Therapeutics NASDAQ:ITRM

Pulmatrix NASDAQ:PULM

Sonoma Pharmaceuticals NASDAQ:SNOA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ITRM, PULM, GELS, and SNOA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ITRM, PULM, GELS, and SNOA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ITRM, PULM, GELS, and SNOA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ITRM, PULM, GELS, and SNOA Company Descriptions

Gelteq NASDAQ:GELS

Iterum Therapeutics NASDAQ:ITRM

Pulmatrix NASDAQ:PULM

Sonoma Pharmaceuticals NASDAQ:SNOA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools